BioAdaptives, Inc. has recently filed a report detailing a stock transaction involving Series D Convertible Preferred Stock. This filing, dated October 6, 2026, is significant as it illustrates the company's ongoing activities in the pharmaceutical preparations industry.
Background
BioAdaptives, Inc. operates within the pharmaceutical preparations sector, classified under SIC 2834. The company, which trades under the ticker symbol BDPT on the OTC exchange, has been active in various filings, including recent Form 4 submissions. The latest filing follows a series of transactions and reports, indicating ongoing corporate actions.
What the Filing Says
The filing reveals that Mark P. Frissora, a director at BioAdaptives, acquired 15,625 shares of Series D Convertible Preferred Stock on October 1, 2026. The shares were issued as compensation for his services on the board. The filing states, "Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person." Following this transaction, Frissora owns a total of 155,265 shares.
Impact
This transaction may affect the company's governance and investor perception as it reflects the compensation structure for board members. As BioAdaptives continues to engage in such transactions, it may influence how stakeholders view the alignment of executive interests with company performance. The filing indicates that Frissora's shares of Series D Convertible Preferred Stock are convertible into common stock, which could further impact shareholder dynamics.
What's Next
The filing does not say what happens next.